SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending due to its upcoming removal from the Nasdaq 100, triggering anticipated selling pressure from tracking funds and prompting concern about further index exclusions. Community sentiment is largely negative, with some investors discussing potential bottom-fishing strategies while others express frustration with the company's leadership and performance. Discussions also include the company's valuation relative to its growth and the broader ad tech sector.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is trending amid community excitement, with many pointing to its potential within the Ethereum ecosystem and its compelling narrative rooted in meme culture. Discussions highlight its strong community, steady price action, and the belief that it's gearing up for a significant breakout, possibly as the next big meme token.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is gaining traction due to its high throughput, processing millions of transactions per second, and its potential to become a compliant infrastructure solution for traditional finance. The project's interoperability with other chains and integration with a Stripe company, Bridge, are also key talking points. Community discussions revolve around Keeta's infrastructure edge and possible undervaluation compared to competitors.

RYTHM, Inc. engages in the development of hardware and software solutions for indoor agriculture. The company was founded on June 6, 2016 and is headquartered in Rolling Meadows, IL.

RYTHM Inc.

RYM is experiencing volatility, driven by community discussions around its potential in the cannabis sector. The stock's movements are being attributed to factors like news, short covering, and overall market sentiment towards weed stocks. Traders are actively debating entry and exit points, as well as potential price targets.

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Innoviva Inc

Innoviva ($INVA) is trending following FDA approval of NUZOLVENCE (zoliflodacin) for treating uncomplicated gonorrhea. While the approval is a positive catalyst, community discussion centers on the lack of an immediate commercial launch plan, potential partnerships, and how the drug stacks up against competitor Blujepa. Some investors believe the market is undervaluing the news, awaiting further details on Innoviva's commercial strategy.

Coca-Cola Consolidated, Inc. engages in the production, marketing, and distribution of nonalcoholic beverages. It operates through the Non-Alcoholic Beverages and All Other segments. Its products include sparkling and still beverages as well as energy products and noncarbonated beverages such as bottled water, tea, ready to drink coffee, enhanced water, juices, and sports drinks. The company was founded by J. B. Harrison in 1902 and is headquartered in Charlotte, NC.

Coca-Cola Consolidated Inc

Coca-Cola Consolidated ($COKE) is trending as community members discuss recent actionable trade alerts and potential ROI. Bullish sentiment is suggested by the stock trading above its moving averages, with some eyeing targets significantly higher. Despite general market uncertainty, $COKE's perceived stability and unique bottling business model are generating interest.

Forget What You Know. This is Qubic.  Qubic is a decentralised Layer 1 network, where unmatched scalable tech meets artificial general intelligence (AGI), purpose built from the ground up to transcend the traditional limitations of blockchain.  Qubic is redefining blockchain with feeless transactions and instant finality, and a unique PoW model (Useful Proof of Work) that channels computational power toward AI training, rather than wasting it. This is a network where mining serves a higher purpose.  Qubic's network can empower industries such as finance, gaming, and supply chain management with real-time, cost-free transactions. Its architecture enables high-performance dApps encouraging developers to build reliable and scalable solutions.   Useful Proof of Work (uPoW): Unlike traditional PoW, which wastes vast amounts of energy, uPoW focuses computational power on AI training, making mining meaningful.   Aigarth Initiative: Aigarth lies at the core of Qubic's mission to achieve AGI. Through this initiative, computational power is generated by a global network of miners and channelled via UPoW towards artificial intelligence training with the aim of developing AGI by 2027. Aigarth represents Qubic's vision of a decentralised, community-powered AI network where advancements in AI are accessible to all, not controlled by any single interest.  Bare Metal Architecture: Running directly on bare metal hardware, removing the need for an operating system, enables Qubic to maximise performance, enabling unmatched scalability and high-volume processing.  Instant Finality: Qubic's sub-second finality ensures nearly instantaneous transactions, essential for applications needing real-time performance.   Feeless Transactions: Qubic’s zero-fee model eliminates cost barriers, encouraging wider adoption and participation.   Smart Contracts and IPOs: Qubic boasts the world’s fastest smart contracts, achieving up to 55 million transfers per second. It also redefines smart contracts. Investors can bid for shares when a new Qubic smart contract is released via an IPO.    Quorum Consensus: Inspired by Leslie Lamport’s Byzantine Fault Tolerance, Qubic’s Quorum design ensures security and resilience even if some nodes fail. With foundations in Nick Szabo’s decentralised trust principles, Qubic’s governance prevents any single entity from gaining control, maintaining a secure and truly decentralised network.  Become part of the Qubic ecosystem, where decentralised blockchain and AI unite. Visit our website, become a miner or a developer, or engage with the Qubic community as we work together to redefine blockchain technology and AI for a new era.

Qubic 

Qubic is gaining attention as discussions revolve around its potential in the AI space and recent developments, including exchange listings and airdrops. The community is focused on its technology, with some speculating about the founder's identity and the project's long-term potential. Recent price movement and roadmap updates have also sparked increased interest.

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ Therapeutics Inc.

LENZ Therapeutics is trending due to a reported case of a retinal tear associated with its VIZZ eye drops, causing a sharp drop in share value as investors weigh safety concerns. While the company reassured the single case rate is low and the patient had pre-existing retinal issues, the community is actively discussing the market's overreaction and potential short squeeze opportunities, with some viewing this as a generational buying opportunity.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending as traders discuss its low float and potential for a significant breakout, drawing comparisons to other recent high-flying stocks. Community members highlight the stock's bullish setup and recent price action above a key technical level. The conversation also suggests possible short covering and accumulation by large shareholders.

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Holding AG - ADR

Roche Holdings AG ADR

Roche Holding AG ($RHHBY) is trending following positive breast cancer study results for giredestrant, which significantly reduced the risk of invasive disease recurrence or death. Community members are actively discussing the potential implications of this data, including comparing it to other potential investments like $OLMA and $GANX, with some speculating about potential acquisitions or bidding wars. The news underscores Roche's continued focus on developing next-generation endocrine therapies and solidifying its position in the breast cancer treatment landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

Equity

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.


Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

SRNE
Sorrento Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SRNE News

SRNESorrento Therapeutics Inc